RECOVER-Autonomic: Ivabradine Alone Did Not Improve Orthostatic Intolerance in Post-COVID POTS, But May Have Additional Benefit
Key Points: Postural orthostatic tachycardia syndrome (POTS) is a complex, multisystem disorder…
SPIRIT-HF Trial: No Significant Benefit of Spironolactone in HFpEF or HFmrEF, With Possible Signal of Harm
Key Points: Heart failure with preserved ejection fraction (HFpEF) and heart failure…
Transcutaneous Autonomic Neuromodulation Is Safe But Did Not Reduce BP in Uncontrolled Hypertension: SCRATCH-HTN
Key Points: Despite the availability of multiple effective antihypertensive drug classes, blood…
Mavacamten Improves LVOT Obstruction in Adolescents with Symptomatic Obstructive HCM in Phase 3 SCOUT-HCM Trial
Key Points Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disease,…
Community-Engaged Barbershop-Based Hypertension Prevention in Black Men: Insights from the CLIP Trial
Key Points Black men in the United States experience disproportionately high rates…
Intensive LDL C Targeting to <55 mg/dL Reduced Cardiovascular Events in ASCVD: The Ez-PAVE Trial
Key Points • In the randomized EZ-PAVE trial, an LDL C target…
CHAMPION-AF Trial: LAAOD-WATCHMAN FLX Non-Inferior to NOACs
Key Points For years, left atrial appendage closure has largely been framed…
PCI Improves Angina vs Placebo in Symptomatic Single-Vessel CTO: ORBITA-CTO Trial
Key Points Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is recommended…
Evolocumab Reduces CV Risk in Diabetic Patients Without ASCVD: VESALIUS-CV Trial
Key Points Lowering low-density lipoprotein cholesterol (LDL-C) is a cornerstone of cardiovascular…
KARDINAL Trial: Tonlamarsen Reduces Angiotensinogen Levels but Does Not demonstrate additive SBP Benefit in Single Versus Five Doses
Key Points Hypertension (HTN) remains a leading modifiable cardiovascular risk factor, with many patients exhibiting persistent elevations…
Home-Delivered DASH Diet Groceries Improve BP and LDL-C in African American Patients with Hypertension: The GoFreshRx Trial
Key Points Hypertension (HTN) disproportionately affects African- American adults in the United…
Ultrasound-Facilitated Catheter-Directed Fibrinolysis Reduces Early Clinical Deterioration in Intermediate-Risk Pulmonary Embolism: HI-PEITHO Trial
Key Points Acute pulmonary embolism (PE) remains a leading cause of cardiovascular…
Invasive Coronary Function Testing Identifies High Prevalence of Vasomotor Disorders and Drives Diagnostic Reclassification
Key Points Invasive coronary function testing: Ischemia with nonobstructive coronary arteries (INOCA)…
Asundexian Associated with an Impressive 26% Reduction in Recurrent Stroke Without Increased Bleeding. The OCEANIC-STROKE trial
Asundexian is a direct, potent small molecule inhibitor of Factor XIa (FXIa).…
First-in-human Trial of CRISPR Gene-editing ANGPTL3 Safely Lowered Cholesterol and Triglycerides
Key Points: CTX310 is a first-in-class in vivo CRISPR-Cas9 therapy designed to…
Tirzepatide Lowers MACE vs Dulaglutide in SURPASS-CVOT Patients With Heart Failure
Key Points In SURPASS-CVOT, tirzepatide was previously shown to be non-inferior to…
DAPT-MVD: Extended DAPT reduces MACCE in patients with multi-vessel disease after DES
Key Points: The optimal duration and choice of dual antiplatelet therapy (DAPT)…
NOAC Monotherapy Non-Inferior to Combination Therapy for Net Adverse Clinical events in AF Patients Post–DES: ADAPT AF-DES Trial
Key Points The ADAPT AF-DES randomized trial compared NOAC monotherapy (apixaban or…
Prasugrel Might be a Better Choice than Ticagrelor For DAPT after PCI for Patients with Diabetes and MVD: The TUXEDO-2 Trial
Key Points TUXEDO-2 directly compared ticagrelor vs prasugrel based DAPT in 1,800…
POLY-HF: Polypill for HFrEF Shows Promise in Reducing Medication Burden Among Underserved Patients
Key Points: Patients with heart failure with reduced ejection fraction (HFrEF) often…